Biomarkers in the Evaluation of Chronic… | Clinical Trial

Key information

Conditions

Pulmonary Hypertension Cardiovascular Diseases Hypertension Hypertension, Pulmonary Interstitial Lung Disease Lung Diseases Lung Diseases, Interstitial Pulmonary Arterial Hypertension Respiratory Tract Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Interstitial Lung Disease and Pulmonary Hypertension Programs

New Hyde Park, New York, 11040, United States

About this study

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.

To study this hypothesis, we have two specific aims:

To evaluate plasma MIF concentration as a marker of severity in ILD and PH and
To determine the utility of breathe condensate analysis in the evaluation of ILD and PH. If we are successful in identifying MIF as a biomarker, it may identify MIF as a useful therapeutic target, as we have shown in other inflammatory disorders.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject are at least 18 years of age
Subject has confirmed Pulmonary Hypertension and Interstitial Lung Disease
Subject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test.

Exclusion criteria

Subject are pregnant
Subject is unable to perform tasks associated with study

Treatment and study plan

Blood Gas

Other

Subject will have both venous and arterial blood draws to assess for the bloods content of MIF

Pulmonary Exercise Test

Other

Subject will ride exercise bike to assess their pulmonary function level.

Spirometry

Other

To assess subjects lung function

Breath Condensate Collector

Other

Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.

Sponsors and collaborators

Lead sponsor

Northwell Health

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Jun 23, 2009
Registry last updated: May 27, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed